• Provectus Biopharmaceuticals posted a net loss of $1.3 million in the quarter ended March 31, 2026, widening 12%.
• Operating loss widened 13.7% to $1.25 million as operating expenses fell 9.3% to $1.25 million.
• Research and development expense dropped 17.2% to $333,334, driven by lower clinical trial and research-related costs on reduced activity levels.
• Grant revenue recorded no revenue versus $278,628 a year earlier, reflecting completion and full recognition of the awarded program in 2025.
• Cash totaled $223,883 at March 31, 2026, while working capital deficit widened to $6.78 million; management flagged substantial doubt about ability to continue as a going concern within one year without additional financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022950), on May 14, 2026, and is solely responsible for the information contained therein.